John TD, Walters MC, Rangarajan HG, et al. Incremental eligibility criteria for the BMT CTN 1507 haploidentical trial for children with sickle cell disease. Blood Adv. 2024;8(23):6055-6063.
Saved in:
| Format: | Article |
|---|---|
| Language: | English |
| Published: |
Elsevier
2025-05-01
|
| Series: | Blood Advances |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2473952925001429 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Novel composite health assessment risk model for older allogeneic transplant recipients: BMT-CTN 1704
by: Mohamed L. Sorror, et al.
Published: (2025-07-01) -
Mehta RS, Ramdial J, Kebriaei P, et al. Haploidentical vs HLA-matched sibling donor HCT with PTCy prophylaxis: HLA factors and donor age considerations. Blood Adv. 2024;8(20):5306-5314.
Published: (2025-01-01) -
Impact of posttransplant cyclophosphamide-based GVHD prophylaxis in patients 70 years and older: an update from BMT CTN 1703
by: Sameem Abedin, et al.
Published: (2025-07-01) -
Preventive Use of Azacitidine in Patients with Acute Myeloid Leukemia after Haploidentical Allo-BMT
by: RSh Badaev, et al.
Published: (2018-12-01) -
Paudel BB, Tan S-F, Fox TE, et al. Acute myeloid leukemia stratifies as 2 clinically relevant sphingolipidomic subtypes. Blood Adv. 2024;8(5):1137-1142.
Published: (2025-05-01)